180 Life Sciences Reports $4.1 Million Net Loss and Deteriorating Cash Position for First Half of 2025

180 Life Sciences Corp. reported a net loss of $4.1 million for the six months ending June 30, 2025, compared to a loss of $1.1 million during the same period in 2024. The company's total operating expenses increased to $4.1 million from $3.9 million year-over-year, driven primarily by higher general and administrative costs, which rose to $3.4 million from $3.2 million. The increase in expenses was attributed to stock-based compensation and settlement expenses related to various agreements. Research and development expenses decreased slightly to $423,291 from $484,047, reflecting a strategic shift in resource allocation.

The company’s cash position has also deteriorated, with cash balances dropping to $2.2 million as of June 30, 2025, down from $4.6 million at the end of 2024. This decline in cash is largely due to operational losses, with cash used in operating activities amounting to nearly $2 million in the first half of 2025. The working capital deficit increased to $2.2 million, raising concerns about the company's liquidity and ability to fund ongoing operations. The company anticipates needing to raise significant capital to support its planned iGaming operations and biotechnology initiatives.

In terms of strategic developments, 180 Life Sciences is transitioning into the online gaming industry, having acquired a back-end technology platform from Elray Resources in September 2024. This acquisition is part of a broader strategy to establish a blockchain-based online casino, with plans to initially focus on cryptocurrency gaming. The company is currently evaluating options for a front-end user interface and expects to incur substantial costs to commercialize this new venture, estimating initial expenses could range from $3 million to over $5 million.

Operationally, the company has seen a significant increase in its share count, with 6,039,208 shares of common stock outstanding as of July 22, 2025, compared to 3,176,999 shares at the end of 2024. This increase is partly due to the conversion of Series B Convertible Preferred Stock into common shares. The company has also been actively involved in settlement agreements related to past litigation, which have impacted its financials and operational focus.

Looking ahead, 180 Life Sciences faces substantial challenges, including the need for additional capital to sustain operations and the uncertainty surrounding the commercialization of its iGaming platform and biotechnology assets. The company has indicated that its current cash reserves are expected to last until December 2025, emphasizing the urgency of securing further funding to continue its business operations and meet its financial obligations.